Lexicon Pharmaceuticals LXRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$1.04M+95.9% | -$15.53M+54.0% | -$12.77M+80.3% | $3.25M+106% | -$25.3M+47.7% | ||
| $110K-37.5% | $118K-5.6% | $151K+19.8% | $176K+26.6% | $176K+22.2% | ||
| $3.08M+1.2% | $2.84M+84.5% | $3.44M+23.0% | $3.2M-34.2% | $3.04M-29.3% | ||
| $681K+69.8% | $495K+23.4% | $402K0.0% | $402K-23.4% | $401K-22.4% | ||
| $9.4M+1,016% | —— | —— | -$264K-124% | -$1.03M-299% | ||
| -$5K+83.3% | $123K+130% | -$10K-120% | -$33K-146% | -$30K-123% | ||
| -$6.9M+68.2% | -$5.65M-162% | -$14M-258% | —— | -$21.69M-138% | ||
| $319K+126% | -$1.08M+50.1% | —— | —— | -$1.21M-165% | ||
| $581K-62.3% | $163K+149% | $18K+102% | $21K-98.7% | $1.54M+231% | ||
| -$14.73M+66.4% | -$17.23M+19.8% | -$23.83M+55.6% | —— | -$43.78M+20.6% | ||
| $105.96M+63.1% | $22.17M-14.2% | $26.73M-37.3% | $25.97M-66.3% | $64.97M-64.5% | ||
| $35.7M-66.2% | $27M-66.3% | $78.85M-18.2% | $41.46M-36.2% | $105.55M+44.6% | ||
| -$70.26M-273% | $4.83M— | $52.13M— | $15.48M+226% | $40.58M+137% | ||
| $5M— | $3M— | $0— | $45M— | $0— | ||
| $69.99M— | $0— | $0— | $0+100% | $0-100% | ||
| $2.84M+397% | —— | —— | —— | $572K-66.9% | ||
| $26.55M— | $0— | $0— | $0— | $0-100% | ||
| $88.76M+15,617% | -$2.93M— | $0— | -$45M— | -$572K-100% | ||
| $3.76M+200% | -$15.33M-148% | $28.29M— | -$12.52M— | -$3.77M-105% | ||
| $1.48M-50.2% | $1.69M-46.1% | $1.76M-46.5% | $1.92M-41.0% | $2.97M-8.9% | ||
| $562K-57.6% | $440K-76.7% | $732K-72.9% | $1.21M-63.4% | $1.33M-5.2% | ||
| $681K+69.8% | $495K+23.4% | $402K0.0% | $402K-23.4% | $401K-22.4% | ||
| -$195K-4.8% | -$190K+70.3% | -$191K-8.5% | -$190K-11.1% | -$186K-12.0% | ||
| $319K+126% | -$1.08M+50.1% | —— | —— | -$1.21M-165% | ||
| $581K-62.3% | $163K+149% | $18K+102% | $21K-98.7% | $1.54M+231% | ||
| $35.7M-66.2% | $27M-66.3% | $78.85M-18.2% | $41.46M-36.2% | $105.55M+44.6% | ||
| $26.55M— | $0— | $0— | $0— | $0-100% | ||
| $65K— | $73K— | $0— | $0-100% | $0-100% | ||
| $5M— | $3M— | $0— | $45M— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Lexicon Pharmaceuticals generate?
- Lexicon Pharmaceuticals (LXRX) generated -$99.6M in operating cash flow over the trailing twelve months.
- Where does Lexicon Pharmaceuticals's cash flow data come from?
- Every line is extracted from Lexicon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
